Sign in
Taking people in United StatesPhase 2

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Cincinnati, Portland, and Salt Lake City, United StatesSee the 3 sitesAlso in 7 other countries, 19 sites
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
3 Nov 2025
Expected to end
17 May 2028
Type of study
Interventional
Treatments tested
  • MAS825
Record updated
9 November 2026

Who can take part

Age
1 year and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥ 1 with a diagnosis of Still's Disease
  • Active diseases defined as:
  • CRP or ferritin levels greater than ULN, and any of:; Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or; Rash attributed to Still's Disease activity or; Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or; Serositis or; Macrophage activation syndrome activity as defined by ferritin levels and at least one of: platelet count, a biomarker or fibrinogen levels attributed to Still's Disease activity by the investigator
  • Intolerance or inadequate response to available biologic therapy

Who cannot take part

  • Ongoing or previous treatment with immunomodulatory drugs; A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study
  • Live vaccinations within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose
  • Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy; Still's disease patients with evidence of macrophage activation syndrome are permitted in the study; Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study
  • History of ongoing, chronic or possibly recurrent infection (e.g. HIV, TB, HCV, HBV) and/or symptoms and signs of clinically significant active bacterial, fungal or viral infections
  • History of malignancy of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and metastases
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients
  • Patients out of weight range
  • Glucocorticoid dose exceeding a set limit
  • Pregnant or breastfeeding women
  • Women of child-bearing potential who do not agree to comply with required contraceptive use; Other protocol-defined inclusion/exclusion criteria may apply

Where in United States

Also in 7 other countries, 19 sites

  • Cincinnati Childrens HospitalCincinnati, United StatesContact: Novartis PharmaceuticalsNo longer taking part
  • Legacy Emanuel Research Hosp PortlandPortland, United StatesContact: Brenna BogleTaking people
  • University of UtahSalt Lake City, United StatesContact: Tressie RollinsTaking people

About the trial

What the trial wants to find out

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease

The group in the trial

  • MAS825Treatment being tested

    Experimental drug

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Record updated
9 November 2026